Dosing and Modifications

TALZENNA provides convenient, once-daily dosing1
Dosing image
  • The recommended starting dose of TALZENNA is 1 mg taken orally once daily, with or without food1
  • The 0.25 mg capsule is available for dose reduction1
  • Patients should be treated until disease progression or unacceptable toxicity occurs1
  • The capsules should be swallowed whole and must not be opened or dissolved1
  • If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time1
Dose modifications
For patients who require dose modification, TALZENNA offers flexible dosing options1
Available in 2 capsule strengths: 1 mg capsule and 0.25 mg capsule.
  • To manage adverse reactions, consider interruption of treatment or dose reduction based on severity and clinical presentation
RECOMMENDED STARTING DOSE: 1 mg (one 1 mg capsule) once daily
FIRST DOSE REDUCTION: 0.75 mg (three 0.25 mg capsules) once daily
SECOND DOSE REDUCTION: 0.5 mg (two 0.25 mg capsules) once daily
THIRD DOSE REDUCTION: 0.25 mg (one 0.25 mg capsule) once daily
Treatment with TALZENNA should be discontinued if more than 3 dose reductions are required.
Dose modification for adverse reactions1
Monitor complete blood counts monthly and as clinically indicated.
Recommended dose modifications and management for adverse reactions.
Dose modifications for patients with renal impairment1
  • For patients with moderate renal impairment (CLcr 30-59 mL/min), the recommended dose of TALZENNA is 0.75 mg once daily
  • For patients with severe renal impairment (CLcr 15-29 mL/min), the recommended dose of TALZENNA is 0.5 mg once daily
Dose modifications for use with P-glycoprotein (P-gp) inhibitors1
  • Reduce the TALZENNA dose to 0.75 mg once daily when coadministered with certain P-gp inhibitors*
  • When the P-gp inhibitor is discontinued, increase the TALZENNA dose (after 3-5 half-lives of the P-gp inhibitor) to the dose used prior to the initiation of the P-gp inhibitor
*In the clinical studies, coadministration with P-gp inhibitors, including amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil, resulted in an approximate 45% increase in TALZENNA exposure and an increase in the rate of TALZENNA dose reduction.
  1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc.; 2020.
  2. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763.